Skip to content

Rapid Micro Biosystems RPID Finance Lease, Right-of-Use Asset, after Accumulated Amortization

Finance Lease, Right-of-Use Asset, after Accumulated Amortization at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$8.0M+11.1%
Gross profit$371.0K-8.2%
Operating income-$13.9M-18.8%
Net income-$14.3M-26.7%
EPS (diluted)-$0.31-19.2%

Balance sheet

See full
Cash & equivalents$14.1M-26.8%
Total debt$23.8M+301%
Total equity$20.4M-68.9%
Total assets$62.4M-27.0%

Cash flow

See full
Operating cash flow-$15.1M-66.1%
CapEx$394.0K+23.5%
Free cash flow-$15.5M-64.7%

Valuation

See full
Market cap$86.19M-43.8%
Enterprise value$95.86M-31.7%
P/S2.5×-2.6×

Profitability

See full
Operating margin-144.2%-12.7pp
Net margin-145.8%-5.0pp
FCF margin-110.5%-14.9pp

Returns & leverage

See full
Return on equity-116.7%-620pp
Debt / equity1.2×+1.1×
Current ratio2.6×-2.0×

Where this comes from

Reported directly by Rapid Micro Biosystems in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAsset.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's finance lease, right-of-use asset, after accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapid Micro Biosystems's finance lease, right-of-use asset, after accumulated amortization?
Rapid Micro Biosystems (RPID) reported finance lease, right-of-use asset, after accumulated amortization of $119K in Q1 2026.
How has Rapid Micro Biosystems's finance lease, right-of-use asset, after accumulated amortization changed year-over-year?
Rapid Micro Biosystems's finance lease, right-of-use asset, after accumulated amortization decreased by 23.7% year-over-year, from $156K to $119K.
What is the long-term trend for Rapid Micro Biosystems's finance lease, right-of-use asset, after accumulated amortization?
Over 3 years (2022 to 2025), Rapid Micro Biosystems's finance lease, right-of-use asset, after accumulated amortization has grown at a -25.9% compound annual growth rate (CAGR), from $317K to $129K.